Welcome to our dedicated page for Kymera Therapeutics SEC filings (Ticker: KYMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biotechnology company focused on targeted protein degradation (TPD). Through these filings, investors can review how Kymera reports its clinical progress, collaboration agreements, financing activities and corporate governance matters.
Kymera’s current reports on Form 8-K disclose material events such as clinical data presentations for KT-621, an investigational first-in-class oral STAT6 degrader in atopic dermatitis and asthma, and updates on KT-579, an oral IRF5 degrader for immune-mediated diseases. 8-K filings also describe key collaboration developments, including the IRAK4 degrader KT-485/SAR447971 with Sanofi for immuno-inflammatory diseases and an exclusive option and license agreement with Gilead Sciences covering an oral CDK2 molecular glue degrader program for potential use in breast cancer and other solid tumors.
Filings related to public offerings and capital structure outline Kymera’s underwritten offerings of common stock and pre-funded warrants, shelf registration statements on Form S-3 and associated underwriting agreements and registration rights agreements. These documents explain how the company raises capital to advance its pipeline of preclinical and clinical degrader programs and may detail potential milestone and royalty structures under collaboration arrangements.
Users can also consult SEC filings for information on Nasdaq listing details, including the KYMR ticker on The Nasdaq Global Market, as well as shareholder meeting results, board composition and executive transitions. Stock Titan’s platform pairs these filings with AI-powered summaries that highlight key terms, material developments and financial implications, helping readers navigate complex documents such as 8-Ks, registration statements and related exhibits more efficiently.
Kymera Therapeutics director Elena Ridloff exercised stock options covering 12,000 shares of common stock at an exercise price of $14.18 per share, then sold 12,000 shares in open-market transactions at weighted average prices around $85–$86 under a pre-arranged Rule 10b5-1 trading plan, leaving no directly held common shares reported.
Kymera Therapeutics, Inc. Chief Operating Officer Jeremy G. Chadwick reported a series of option exercises and related stock sales in Kymera common stock. He exercised stock options covering 22,240 shares at an exercise price of $29.64 per share on March 31 and April 1, 2026, converting derivative positions into common shares.
On the same dates, he sold 22,240 shares of common stock in open-market transactions at weighted average prices between $85.02 and $85.97 per share, pursuant to a pre-established Rule 10b5-1 trading plan dated December 10, 2025. Following these transactions, he directly owns 61,202 shares of Kymera common stock.
KYMR reported a proposed sale of 4,600 shares of Common Stock via exercise of stock options to be effected on 04/01/2026 through Morgan Stanley Smith Barney LLC. The filing also records prior 10b5-1 sales by Elena Ridloff of 7,400 shares on 03/31/2026 for $631,738.74.
Form 144 filed reporting a proposed sale of 14,640 shares of Common Stock. The filing lists the sale as an Exercise of Stock Options with proceeds shown and a trade date of 04/01/2026. The submission also lists multiple prior 10b5-1 sales by Jeremy Chadwick in March 2026, including 91,250 shares on 03/23/2026 and 24,727 shares on 03/25/2026.
KYMR affiliate reported multiple sales of Common Stock under a Rule 10b5-1 plan and an exercise-based sale. The filing lists 10b5-1 dispositions on 03/25/2026 (24,727 shares, $1,984,554.44), 03/23/2026 (91,250 shares, $7,063,733.26), 03/11/2026 (25,758 shares, $2,145,673.70), and earlier March trades. The filing also shows an exercise of stock options for 7,600 shares on 03/31/2026 with cash consideration.
Kymera Therapeutics, Inc. reported that its Board of Directors approved an immediate amendment to the company’s Second Amended and Restated Bylaws. The change designates the federal district courts of the United States as the exclusive forum for any complaints asserting causes of action under the Securities Act of 1933 or the Securities Exchange Act of 1934, and related regulations, unless the company agrees in writing to a different forum.
The amendment aligns the company’s bylaws with recent changes to the Delaware General Corporation Law regarding forum selection provisions. The full text of the amendment is provided as an exhibit to the report for shareholders and other stakeholders who want to review the precise language.
The Vanguard Group filed Amendment No. 4 to a Schedule 13G/A reporting 0 shares of Kymera Therapeutics Inc. common stock. The filing states that an internal realignment effective January 12, 2026 led certain Vanguard subsidiaries/divisions to report holdings separately under SEC Release No. 34-39538. The amendment, signed 03/27/2026, lists 0 shares beneficially owned and 0% ownership of the class.
Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick reported a series of option exercises and share sales in Kymera Therapeutics, Inc. common stock. He exercised stock options to acquire 109,127 shares at an exercise price of $29.64 per share and then sold 115,977 shares of common stock in multiple open-market transactions at weighted average prices ranging from the mid-$70s to about $80 per share, as detailed in the footnotes. Following these transactions, he directly held 61,202 shares of Kymera common stock. The filing states that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan dated December 10, 2025, indicating they were scheduled in advance rather than timed discretionarily.
KYMR notice reports Rule 144 transactions in Common stock by an insider and planned issuer-related issuances. The filing lists 109,127 shares tied to an exercise of stock options on 03/23/2026 and 6,850 shares issued as Restricted Stock Units on 03/01/2026. The filing also discloses recent 10b5-1 sales: 25,758 shares on 03/11/2026 for $2,145,673.70, 3,919 shares on 03/04/2026 for $334,272.49, and 2,039 shares on 03/02/2026 for $181,321.64.